ClinicalTrials.gg
CompletedNCT00424268HELIOSUpdated Dec 5, 2016Results posted

Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)

A Phase 3 interventional study of Roflumilast and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 103 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-05.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
743
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
11th of 32
743 · median 154
Started
2007
the only one that year
Phase 3
16 of 32
none open now
Registered
10th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 11th largest by enrollment, is the only one that started in 2007, is one of 16 in phase 3, and was the 10th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of tiotropium. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Roflumilast
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • History of for at least 12 months prior to baseline visit and chronic productive cough for 3 months in each of the 2 years prior to baseline visit
  • /FVC ratio (post-bronchodilator) ≤ 70%
  • FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted
  • Treated with tiotropium for at least 3 months before enrollment
  • At least 28 puffs of rescue medication during last week prior to randomization

Main Exclusion Criteria:

  • COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
743 participants (actual)

Study arms

  • Active comparator
    Roflumilast

    Roflumilast 500 µg underlying medication: tiotropium 18 µg, once daily, inhaled

    Drug: Roflumilast

  • Placebo comparator
    Placebo

    Placebo underlying medication: tiotropium 18 µg, once daily, inhaled

    Drug: Placebo

Interventions

  • 500 µg, once daily, oral administration in the morning

  • DrugPlacebo

    once daily

06

What researchers measure

Primary outcomes

  1. Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)

    Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \[L\]

    Time frame: Change from baseline over 24 weeks of treatment

Secondary outcomes

  1. Post-bronchodilator FEV1

    Mean change from baseline during the treatment period in post-bronchodilator FEV1 \[L\]

    Time frame: Change from baseline over 24 weeks of treatment

  2. COPD Exacerbation Rate (Moderate or Severe)

    Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\].

    Time frame: 24 weeks treatment period

  3. Transition Dyspnea Index (TDI) Focal Score

    The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.

    Time frame: Change from baseline over 24 weeks of treatment

  4. Shortness of Breath Questionnaire (SOBQ) Total Score

    Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is "not at all breathless" and five is "maximally breathless or too breathless to do the activity".

    Time frame: Change from baseline over 24 weeks of treatment

07

Results

Posted May 19, 2011

Participant flow

Participant flow — Overall Study
MilestoneRoflumilastPlacebo
Started371372
Completed309333
Not completed6239

Outcome measures

PrimaryPre-bronchodilator Forced Expiratory Volume in First Second (FEV1)

Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \[L\]

Time frame:
Change from baseline over 24 weeks of treatment
Reported as:
Least squares mean · mL
Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
mLRoflumilastPlacebo
Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)65 ± 12-16 ± 12
Statistical analysis
  • Roflumilast vs Placebo · ANCOVA · p = <0.0001 (No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.) · Mean difference (net): 80 · 95% CI 51 to 110Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).
SecondaryPost-bronchodilator FEV1

Mean change from baseline during the treatment period in post-bronchodilator FEV1 \[L\]

Time frame:
Change from baseline over 24 weeks of treatment
Reported as:
Least squares mean · mL
Post-bronchodilator FEV1
mLRoflumilastPlacebo
Post-bronchodilator FEV174 ± 12-7 ± 11
Statistical analysis
  • Roflumilast vs Placebo · ANCOVA · p = <0.0001 (No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.) · Mean difference (net): 81 · 95% CI 51 to 110Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).
SecondaryCOPD Exacerbation Rate (Moderate or Severe)

Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\].

Time frame:
24 weeks treatment period
Reported as:
Mean · exacerbations per patient per year
COPD Exacerbation Rate (Moderate or Severe)
exacerbations per patient per yearRoflumilastPlacebo
COPD Exacerbation Rate (Moderate or Severe)0.262 (0.184 to 0.375)0.342 (0.248 to 0.472)
Statistical analysis
  • Roflumilast vs Placebo · Poisson regression · p = 0.1957 (No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.) · Rate ratio: 0.768 · 95% CI 0.515 to 1.146
SecondaryTransition Dyspnea Index (TDI) Focal Score

The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.

Time frame:
Change from baseline over 24 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Transition Dyspnea Index (TDI) Focal Score
scores on a scaleRoflumilastPlacebo
Transition Dyspnea Index (TDI) Focal Score1.4 ± 0.10.9 ± 0.1
Statistical analysis
  • Roflumilast vs Placebo · ANCOVA · p = 0.0032 (This secondary endpoint was analyzed in an exploratory manner.) · Mean difference (final values): 0.4 · 95% CI 0.1 to 0.7Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).
SecondaryShortness of Breath Questionnaire (SOBQ) Total Score

Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is "not at all breathless" and five is "maximally breathless or too breathless to do the activity".

Time frame:
Change from baseline over 24 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Shortness of Breath Questionnaire (SOBQ) Total Score
scores on a scaleRoflumilastPlacebo
Shortness of Breath Questionnaire (SOBQ) Total Score-3.4 ± 0.7-0.7 ± 0.7
Statistical analysis
  • Roflumilast vs Placebo · ANCOVA · p = 0.0051 (This secondary endpoint was analyzed in an exploratory manner.) · Mean difference (net): -2.6 · 95% CI -4.5 to -0.8Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).

Adverse events

Collected over 24 weeks treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast—22/374 (5.9%)106/374 (28.3%)
Placebo—21/369 (5.7%)76/369 (20.6%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventRoflumilastPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/3745/369
HaematocheziaGastrointestinal disorders2/3740/369
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/3741/369
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/3741/369
Angina pectorisCardiac disorders0/3741/369
Atrioventricular block completeCardiac disorders0/3741/369
Cardiac failureCardiac disorders0/3741/369
Myocardial infarctionCardiac disorders0/3741/369
Ventricular tachycardiaCardiac disorders0/3741/369
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3741/369
Most frequent other events
Most frequent other events
EventRoflumilastPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders54/37463/369
DiarrhoeaGastrointestinal disorders33/3742/369
NasopharyngitisInfections and infestations21/37420/369
Weight decreasedInvestigations20/3742/369

Baseline characteristics

Age, Continuous
Age, Continuous(years)RoflumilastPlaceboTotal
Mean64.2 ± 9.164.0 ± 9.364.1 ± 9.2
Gender
Gender(Participants)RoflumilastPlaceboTotal
Female109105214
Male262267529
08

Study locations

103 sites
  • Altana Pharma/Nycomed Investigational Site
    Feldbach, 8330, Austria
  • Altana Pharma/Nycomed Investigational Site
    Gänserndorf, 2230, Austria
  • Altana Pharma/Nycomed Investigational Site
    Hallein, 5400, Austria
  • Altana Pharma/Nycomed Investigational Site
    Linz, 4040, Austria
  • Altana Pharma/Nycomed Investigational Site
    Spittal an der Drau, 9800, Austria
  • Altana Pharma/Nycomed Investigational Site
    Beuvry, 62660, France
  • Altana Pharma/Nycomed Investigational Site
    Chauny Cedex, 2303, France
  • Altana Pharma/Nycomed Investigational Site
    Grasse, 6130, France
  • Altana Pharma/Nycomed Investigational Site
    Lyon, 69003, France
  • Altana Pharma/Nycomed Investigational Site
    Martigues Cedex, 13695, France
  • Altana Pharma/Nycomed Investigational Site
    Montigny-Les-Metz, 57950, France
  • Altana Pharma/Nycomed Investigational Site
    Nantes, 44000, France
  • Altana Pharma/Nycomed Investigational Site
    Nice, 6000, France
  • Altana Pharma/Nycomed Investigational Site
    Nimes Cedex 9, 30029, France
  • Altana Pharma/Nycomed Investigational Site
    Nimes, 30900, France
  • Altana Pharma/Nycomed Investigational Site
    Ollioules, 83190, France
  • Altana Pharma/Nycomed Investigational Site
    Perpignan Cedex, 66046, France
  • Altana Pharma/Nycomed Investigational Site
    Saint Laurent Du Var, 6700, France
  • Altana Pharma/Nycomed Investigational Site
    Saint-Quentin, 2100, France
  • Altana Pharma/Nycomed Investigational Site
    Toulon, 83000, France
  • Altana Pharma/Nycomed Investigational Site
    Bad Homburg, 61348, Germany
  • Altana Pharma/Nycomed Investigational Site
    Dortmund, 44263, Germany
  • Altana Pharma/Nycomed Investigational Site
    Geesthacht, 21502, Germany
  • Altana Pharma/Nycomed Investigational Site
    Gelnhausen, 63571, Germany
  • Altana Pharma/Nycomed Investigational Site
    Göppingen, 73033, Germany
  • Altana Pharma/Nycomed Investigational Site
    Hannover, 30167, Germany
  • Altana Pharma/Nycomed Investigational Site
    Koblenz, 56068, Germany
  • Altana Pharma/Nycomed Investigational Site
    Landsberg/Lech, 86899, Germany
  • Altana Pharma/Nycomed Investigational Site
    Leonberg, 71229, Germany
  • Altana Pharma/Nycomed Investigational Site
    Marburg, 35037, Germany
  • Altana Pharma/Nycomed Investigational Site
    Saarbrücken, 66111, Germany
  • Altana Pharma/Nycomed Investigational Site
    Saarlouis, 66740, Germany
  • Altana Pharma/Nycomed Investigational Site
    Schwetzingen, 68723, Germany
  • Altana Pharma/Nycomed Investigational Site
    Sinsheim, 74889, Germany
  • Altana Pharma/Nycomed Investigational Site
    Weyhe, 28844, Germany
  • Altana Pharma/Nycomed Investigational Site
    Witten, 58452, Germany
  • Altana Pharma/Nycomed Investigational Site
    Budapest, 1046, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Budapest, 1134, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Budapest, 1529, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Cegled, 2700, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Csorna, 9300, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Erd, 2030, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Györ, 9024, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Hódmezovásárhely, 6800, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Matrahaza, 3233, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Nyiregyháza, 4412, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Szentes, 6600, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Szolnok, 5006, Hungary
  • Altana Pharma/Nycomed Investigational Site
    Bassano Del Grappa (VI), 36061, Italy
  • Altana Pharma/Nycomed Investigational Site
    Cisanello (PI), 56100, Italy
  • Altana Pharma/Nycomed Investigational Site
    Foggia, 71100, Italy
  • Altana Pharma/Nycomed Investigational Site
    Genova, 16132, Italy
  • Altana Pharma/Nycomed Investigational Site
    Milano, 20153, Italy
  • Altana Pharma/Nycomed Investigational Site
    Modena, 41100, Italy
  • Altana Pharma/Nycomed Investigational Site
    Pavullo nel Frignano (MO), 41020, Italy
  • Altana Pharma/Nycomed Investigational Site
    Pordenone, 33170, Italy
  • Altana Pharma/Nycomed Investigational Site
    Reggio Emilia, 42100, Italy
  • Altana Pharma/Nycomed Investigational Site
    Verona, 30012, Italy
  • Altana Pharma/Nycomed Investigational Site
    Alicante, 3010, Spain
  • Altana Pharma/Nycomed Investigational Site
    Baracaldo (Vizcaya), 48903, Spain
  • Altana Pharma/Nycomed Investigational Site
    Candia, 28935, Spain
  • Altana Pharma/Nycomed Investigational Site
    Escaldes-Engordany, AD700, Spain
  • Altana Pharma/Nycomed Investigational Site
    Galdakao, 48960, Spain
  • Altana Pharma/Nycomed Investigational Site
    Guadalajara, 19002, Spain
  • Altana Pharma/Nycomed Investigational Site
    Jerez de la Frontera, 11407, Spain
  • Altana Pharma/Nycomed Investigational Site
    La Coruna, 15006, Spain
  • Altana Pharma/Nycomed Investigational Site
    Lleida, 25198, Spain
  • Altana Pharma/Nycomed Investigational Site
    Lugo, 27004, Spain
  • Altana Pharma/Nycomed Investigational Site
    Madrid, 28007, Spain
  • Altana Pharma/Nycomed Investigational Site
    Madrid, 28034, Spain
  • Altana Pharma/Nycomed Investigational Site
    Madrid, 28047, Spain
  • Altana Pharma/Nycomed Investigational Site
    Mostoles Madrid, 28935, Spain
  • Altana Pharma/Nycomed Investigational Site
    Pozuelo de Alarcón, 28223, Spain
  • Altana Pharma/Nycomed Investigational Site
    Requena, 46340, Spain
  • Altana Pharma/Nycomed Investigational Site
    Sant Cugat del Valles, 8190, Spain
  • Altana Pharma/Nycomed Investigational Site
    Santa Cruz de Tenerife, 38010, Spain
  • Altana Pharma/Nycomed Investigational Site
    Sevilla, 41013, Spain
  • Altana Pharma/Nycomed Investigational Site
    Valencia, 46010, Spain
  • Altana Pharma/Nycomed Investigational Site
    Valencia, 46014, Spain
  • Altana Pharma/Nycomed Investigational Site
    Valencia, 46015, Spain
  • Altana Pharma/Nycomed Investigational Site
    Valencia, 46017, Spain
  • Altana Pharma/Nycomed Investigational Site
    Ashford, TW15 3RN, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Atherstone, Warwick, CV9 1EU, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Barry, CS62 7EB, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Bexhill-on-Sea, East Sussex, TN40 1JJ, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Bolton Lancs, BL3 6TL, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Bolton, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Chesterfield Derbyshire, S40 4TF, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Chesterfield, S40 4TF, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Chippenham, SN15 1HP, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Co. Antrim, BT38 8TP, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Darlington, Co. Durham, DL3 6HX, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    East Sussex, TN39 5HE, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Glasgow, G45 9AW, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Harrow, HA3 7LT, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Keresely End, Coventry, CV7 8LA, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Plymouth, PL6 7TH, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Sheffield, S39DA, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Solihull, B91 2JL, United Kingdom
  • Altana Pharma/Nycomed Investigational Site
    Swindon, Wilts, SN25 4YZ, United Kingdom

Showing the first 100 of 103 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6. PubMed 19716961 ↗
  • Cazzola M, Picciolo S, Matera MG. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opin Pharmacother. 2010 Feb;11(3):441-9. doi: 10.1517/14656560903555201. PubMed 20102307 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jan 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2007
First posted
Jan 19, 2007
Start
Jan 2007
Primary completionActual
Jan 2008
CompletionActual
Jul 2008
Results first posted
May 19, 2011
Last update
Dec 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424268
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 19, 2007
Start date
Jan 2007
Primary completion
Jan 2008
Completion
Jul 2008
Results posted
May 19, 2011
Last update
Dec 5, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion